von Euler M.,Karolinska Institutet |
Johnsson H.,Karolinska University Hospital |
Holmstrom M.,Karolinska Universitetssjukhuset Koagulationsmottagningen |
Wettermark B.,Stockholm County Council HSF Stockholm |
Hjemdahl P.,Karolinska Institutet
Läkartidningen | Year: 2015
Since the introduction of NOAC (non-vitamin K antagonist oral anticoagulants) in 2011 as thromboprophylactic treatment for patients with atrial fibrillation, AF, the number of patients with a diagnosis of atrial fibrillation has increased markedly in our health care registers. The proportion of patients treated with warfarin or NOAC has increased from 47 % to 58 % in 2013. The use of acetylsalicylic acid in patients is decreasing rapidly in patients with AF. NOAC are mostly prescribed by specialists and are mainly used in younger patients with lower CHA2DS2-VASc scores and lower risk for renal insufficiency and bleeding.